Skip to main content

Table 2 Summary of adverse events

From: Safety and effectiveness of switching to Abacavir/Lamivudine plus rilpivirine for maintenance therapy in virologically suppressed HIV-1 individuals in Singapore (SEALS)

 

n

Summary of adverse effects

 Total number of adverse effects

49

 Individuals with ≥ 1 adverse effects

31

 Individuals who discontinued therapy due to adverse effects

13

Types of adverse effects

 Neuro-psychiatric (i.e. forgetfulness, insomnia, mood changes, vivid dreams)

26

 Digestive (i.e. abdominal pain, stomach-ache)

11

 Dermatological (i.e. rash)

4

 Others (e.g. fatigue, lipodystrophy, gynecomastia)

8